Medigene announced a $1M milestone payment from Regeneron (REGN) was triggered. Regeneron purchased the MAGE-A4-TCR program as part of its acquisition of 2seventy Bio’s (TSVT) pre-clinical and clinical oncology and autoimmune cell therapy pipeline, which closed in April. The payment was triggered by a development milestone for a trial in China led by JW Therapeutics of Regeneron’s MAGE-A4 cell therapy, which contains a Medigene generated T cell receptor targeting MAGE-A4e
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue